Neuland Laboratories Limited: Business Overview, Financials & Competitive Analysis
Neuland Laboratories Limited scores 8/10 on the AskCyborg Cyborg Score (Strong). Fundamentally strong API manufacturer with compelling growth tailwinds from supply chain diversification, supported by strong analyst conviction and dual revenue streams in stable generics and high-margin custom synthesis. Neuland demonstrates robust growth metrics with strong analyst consensus (100% BUY ratings), expanding export capacity ($20.4M monthly exports reported), and dominant.
What is Neuland Laboratories Limited's industry? Neuland Laboratories Limited (neulandlabs.com) operates in Pharmaceuticals & Biotechnology - Active Pharmaceutical Ingredient Manufacturing & Contract Development Manufacturing Organization (CDMO). AskCyborg classifies Neuland Laboratories Limited under Pharmaceuticals & Biotechnology - Active Pharmaceutical Ingredient Manufacturing & Contract Development Manufacturing Organization (CDMO) in its company registry.
Neuland Laboratories is a leading Indian CDMO (Contract Development and Manufacturing Organization) that manufactures active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs for global pharm...
Cyborg Score thesis
Fundamentally strong API manufacturer with compelling growth tailwinds from supply chain diversification, supported by strong...
Read the full analyst-debate transcript →Get the Latest Neuland Laboratories Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNeuland Laboratories Limited Overview
Pro stress-test →Neuland Laboratories is a leading Indian CDMO (Contract Development and Manufacturing Organization) that manufactures active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs for global pharma and biotech markets. Founded in 1984 and headquartered in Hyderabad, the company exports to over 35 countries and serves both domestic and international customers through two core business verticals.
Strategic Profile
Pro stress-test →The company operates dual business models: Generic Drug Substances (GDS) with 100+ mature APIs including flagship molecules Levetiracetam and Mirtazapine, and Custom Manufacturing Solutions (CMS) supporting biotech innovators through clinical development to commercial launch. With strong recent financial momentum (44% EPS CAGR over 5 years, 940% TSR), Neuland is benefiting from global API market consolidation and India's growing prominence in specialty chemical manufacturing amid supply chain diversification away from China.
Competitive Landscape
Pro stress-test →Neuland competes in India's fragmented but consolidating API manufacturing sector. Key competitors include Divi's Laboratories (₹51B+ market cap, 19.3% FY25 revenue growth) and Laurus Labs, which similarly serve global generic and specialty pharma segments. Neuland's differentiation lies in niche API specialization, vertically integrated manufacturing across 3 facilities, and emerging peptide capabilities—positioning it to capture share as multinational pharma companies diversify sourcing away from China.
Industry Context
Neuland Laboratories Limited operates in Pharmaceuticals & Biotechnology - Active Pharmaceutical Ingredient Manufacturing & Contract Development Manufacturing Organization (CDMO).
Key facts
Founded: 1984 · Headquarters: Hyderabad, India · Employees: Not disclosed · Revenue: ₹516Cr+ (Q2 FY26 quarterly basis; ~₹2,000Cr+ annualized) · Market cap: ₹169-171B (~$20.2-20.5B USD equivalent)